awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26747678-3DD424D4-6BE3-4E5C-92F3-D589C630F1E4
Q26747678-3DD424D4-6BE3-4E5C-92F3-D589C630F1E4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26747678-3DD424D4-6BE3-4E5C-92F3-D589C630F1E4
Tumor refractoriness to anti-VEGF therapy
P2860
Q26747678-3DD424D4-6BE3-4E5C-92F3-D589C630F1E4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26747678-3DD424D4-6BE3-4E5C-92F3-D589C630F1E4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ac8e6aeab17b5a44cea22a732a3fada3151ce511
P2860
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.